Roblin, D. et al. 2015. Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Dermato-Venereologica. 95, 5 (Feb. 2015), 542–548. DOI:https://doi.org/10.2340/00015555-2047.